Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Avanos Medical, Inc.NYSE: AVNS
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $93.8M rose 20.7% year over year, ahead of the +18.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.
Context
- Cost of revenue amounted to 50.2% of revenue in FY2025, up 5.7 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.7% holds above the trailing-twelve-month pace of +18.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 352.2M USD
- Year-over-year change
- +14.9%
- 4-year CAGR
- -0.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 352.2M | +14.9% |
| FY2024 | 2024-12-31 | 306.5M | +4.4% |
| FY2023 | 2023-12-31 | 293.6M | +1.3% |
| FY2022 | 2022-12-31 | 289.9M | -20.5% |
| FY2021 | 2021-12-31 | 364.7M | — |
Cost of Revenue vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 cost of revenue of $368.3M is the 3rd highest of the 11 companies compared; the peer median is $98.92M.
- Its year-over-year change of +18.2% is the 4th highest of 11, against a peer median of +1.8%.
- Cost of revenue amounts to 51.4% of revenue for AVNS, versus a peer median of 50.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.96B | +35.0% | +16.0% | 46.3% | |
| LTM Apr 2026 | $569.8M | +3.9% | -1.3% | 66.4% | |
| LTM Mar 2026 | $368.3M | +18.2% | +6.7% | 51.4% | |
| LTM Mar 2026 | $185.67M | -0.4% | +0.8% | 32.2% | |
| LTM Mar 2026 | $100.69M | -21.2% | +11.3% | 62.9% | |
| LTM Mar 2026 | $99.22M | -12.1% | -54.4% | 112.4% | |
| LTM Mar 2026 | $98.61M | +11.1% | +15.4% | 48.3% | |
| LTM Mar 2026 | $71.03M | -55.3% | — | 111.9% | |
| LTM Mar 2026 | $44.6M | -34.2% | -11.1% | 51.7% | |
| LTM Mar 2026 | $15.51M | +24.0% | +26.7% | 38.2% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $11.68M | +28.7% | +34.5% | 12.3% |
| Peer median (excluding AVNS) | $98.92M | +1.8% | +11.3% | 50.0% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 744.6M | 684.1M | 673.3M | 687.8M | 701.2M |
| Cost of Revenue | 364.7M | 289.9M | 293.6M | 306.5M | 352.2M |
| Gross Profit | 379.9M | 394.2M | 379.7M | 381.3M | 349M |
| Gross Margin | 51.0% | 57.6% | 56.4% | 55.4% | 49.8% |
| Research & Development | 32.3M | 30.6M | 27.2M | 26.2M | 23.1M |
| Selling, General & Admin | 260.8M | 323.1M | 287.5M | 315.1M | 218.3M |
| Operating Expenses | 293.1M | 352.3M | 314.7M | 341.3M | 410.6M |
| Depreciation & Amortization | 38.3M | 41.1M | 43.5M | 45.5M | 29M |
| EBITDA | 48.9M | 77.8M | 50.6M | (345.6M) | (33.2M) |
| EBITDA Margin | 6.6% | 11.4% | 7.5% | -50.2% | -4.7% |
| Operating Income | 86.8M | 41.9M | 65M | 40M | (61.6M) |
| Operating Margin | 11.7% | 6.1% | 9.7% | 5.8% | -8.8% |
| Interest Income | 200K | 1.2M | 2.9M | 5.1M | 3.2M |
| Interest Expense | 3.3M | 10M | 15M | 12.2M | 4M |
| Other Income / Expenses | (79.5M) | (15.2M) | (72.9M) | (443.3M) | (4.6M) |
| Income Before Tax | 7.3M | 26.7M | (7.9M) | (403.3M) | (66.2M) |
| Pre-Tax Margin | 1.0% | 3.9% | -1.2% | -58.6% | -9.4% |
| Income Tax Expense | 1M | 5.2M | 2M | (17M) | 1.7M |
| Net Income | 6.3M | 50.5M | (61.8M) | (392.1M) | (67.9M) |
| Net Margin | 0.8% | 7.4% | -9.2% | -57.0% | -9.7% |
| EPS (Basic) | 0.13 | 1.08 | (1.33) | (8.53) | (1.46) |
| EPS (Diluted) | 0.13 | 1.07 | (1.33) | (8.53) | (1.46) |
| Weighted Avg Shares | 48.1M | 46.9M | 46.6M | 46M | 46.4M |
| Weighted Avg Shares (Diluted) | 48.6M | 47.3M | 46.6M | 46M | 46.4M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.